Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04)

Exclusion Criteria

• •1. Presence or history of Central Nervous System (CNS) malignancy.
• •2. Patients must not have received chemotherapy within 4 weeks prior to date of consent.
• •3. Performance status \> 1 on the Eastern Cooperative Oncology Group (ECOG) scale.
• •4. Life expectancy \< 6 months.
• •5. Pregnancy or breastfeeding.
• •6. Primary or secondary immunodeficiency, including immunosuppressive disease, and immunosuppressive doses of corticosteroids (e.g. prednisolone \> 7.5mg per day) or other immunosuppressive medications including cyclosporine, azathioprine, interferons, within the past 4 weeks.
• •7. Positive serology for HIV, hepatitis B or hepatitis C.
• •8. Splenectomy.
• •9. Presence of uncontrolled infection.
• •10. Presence of unstable neurological disease.
• •11. Any uncontrolled medical condition that in the opinion of the Investigator is likely to place the patient at unacceptable risk during the study or reduce their ability to complete the study
• •12. Participation in another study requiring administration of an investigational drug or biological agent within the last 4 weeks
• •13. Known allergy to treatment medication or its excipients
• •14. Any other medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent.